Literature DB >> 10948344

Telomerase activity in gliomas with the use of non-radioisotopic and semi-quantitative procedure for terminal repeat amplification protocol.

Y Sugita1, A Nakashima, S Kato, K Sakata, M Morimatsu, M Shigemori.   

Abstract

To study the role of telomerase in the pathogenesis of different grades and subtype of gliomas, telomerase activity in 31 gliomas was assessed with the use of non-radioisotopic and semi-quantitative procedures for the terminal repeat amplification protocol in this study. Among the samples were 17 glioblastoma multiformes (GBMs); 4 anaplastic astrocytomas (AAs); 5 astrocytomas (ASs); 1 ependymoblastoma (EPB); 2 ependymomas (EPs); 1 oligodendroglioma (OG) and 1 medulloblastoma (MB). Postive telomerase activity was detected in 9 of 17 GBMs (53%), 1 of 4 AAs (25%), 1 of 5 ASs (20%), 1 of 1 EPB (100%), and in positive controls, T 98G and KE-1. Weakly positive activity was detected in 2 of 3 AAs (66%) and 2 of 5 ASs (40%). No telomerase activity was detected in 8 of 17 GBMs (47%), 1 of 4 AAs (25%), 2 of 5 AS (40%), 2 of 2 (100%) EPs, 1 of 1 OG (100%), 1 of 1 MB (100%) and normal brain tissue. We defined telomerase expression as positive and weakly positive cases. The percentage of telomerase activity expression in gliomas tended to correlate with tumour grade in spite of histopathology of tumours. These results indicated that the telomerase activity of gliomas may be used as a tumour marker and that the activation of telomerase should correlate with initiation and malignant progression of gliomas. In addition, non-radioisotopic and semi-quantitative procedure for the terminal repeat amplification protocol appears to be the most suitable to detect telomerase activity expression in small neurosurgical specimens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10948344     DOI: 10.3892/or.7.5.1087

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  3 in total

1.  RNA interference mediated downregulation of human telomerase reverse transcriptase (hTERT) in LN18 cells.

Authors:  Ch Lavanya; M K Sibin; M M Srinivas Bharath; M Jeru Manoj; Manjunatha M Venkataswamy; Dhananjaya I Bhat; K V L Narasinga Rao; G K Chetan
Journal:  Cytotechnology       Date:  2016-10-18       Impact factor: 2.058

2.  mRNA quantification and clinical evaluation of telomerase reverse transcriptase subunit (hTERT) in intracranial tumours of patients in the island of Crete.

Authors:  A Yannopoulos; E Dimitriadis; A Scorilas; T Trangas; E Markakis; M Talieri
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640

3.  Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas.

Authors:  A Tchirkov; C Rolhion; J-L Kémény; B Irthum; S Puget; T Khalil; O Chinot; F Kwiatkowski; B Périssel; P Vago; P Verrelle
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.